Y-Mabs Therapeutics, Inc. (YMAB)

Trade YMAB now with
2/17/2021 8:13:13 PM Y-mAbs Therapeutics Prices Public Offering Of 2.44 Mln Shares At $41.00/shr
12/28/2020 9:07:10 AM Y-mAbs Therapeutics To Sell Priority Review Voucher To United Therapeutic
12/18/2020 9:18:21 AM Y-mAbs Therapeutics, Inc Y-mAbs Signs License Agreement With SciClone For DANYELZA And Omburtamab In China
12/4/2020 9:04:37 AM Y-mAbs, Takeda Announce License, Distribution Agreement For DANYELZA, Omburtamab In Israel
7/14/2020 9:08:58 AM Y-mAbs Therapeutics Looks Forward To Further Advancing SADA Technology
4/24/2020 9:14:23 AM Y-mAbs Appoints Laura Hamill To Its Board
12/11/2019 9:10:13 AM Y-mAbs Therapeutics To Present Positive Frontline Data For Naxitamab
11/29/2019 9:10:21 AM Y-mAbs Initiates Rolling Submission Of BLA To FDA For Naxitamab For Treatment Of Neuroblastoma
10/29/2019 10:34:01 PM Y-mAbs Therapeutics Prices Public Offering Of 4.47 Mln Shares At $28.00/shr
10/28/2019 9:08:34 AM Y-mAbs Therapeutics Announces Clinical Update On Omburtamab
7/8/2019 9:13:31 AM Y-mAbs Therapeutics Completes Type B Pre-BLA Meeting With FDA
5/14/2019 9:37:03 AM Y-mAbs Therapeutics Announces Development Update On Cancer Vaccine Program
10/23/2018 9:21:44 AM Naxitamab Gets Positive Opinion For Orphan Medicinal Product Designation Approval In The EU